<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We retrospectively studied 89 consecutive patients diagnosed with primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) over a period of 10 years to (1) identify prognostic factors for overall survival (OS) and <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>); (2) to assess and compare the Bournemouth-, Spanish-, DÃ¼sseldorf-, Lille-, and the International prognostic scoring systems (IPSS); and to (3) compare the French-American-British (FAB) and World Health Organization (WHO) classifications </plain></SENT>
<SENT sid="1" pm="."><plain>The median age of patients was 63 years (range, 26-85) </plain></SENT>
<SENT sid="2" pm="."><plain>Karyotype analyses were done in 85 patients (96%) </plain></SENT>
<SENT sid="3" pm="."><plain>Median OS was 3 years; 67 patients (75%) have died, and 28 (31%) had progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Major independent prognostic variables for both OS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> (multivariate analysis) were percentage of bone marrow (BM) blasts (P &lt; 0.0001), and in patients with cytogenetic data available, cytogenetic risk groups by Lille-score (OS, P = 0.031/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>, P = 0.002) and IPSS (OS, P = 0.024) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> five prognostic scoring systems successfully discriminated risk groups as regards OS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>, but in patients with cytogenetic data available, the major independent prognostic score for OS (P &lt; 0.0001) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> (P = 0.006) was the IPSS </plain></SENT>
<SENT sid="6" pm="."><plain>The FAB and WHO classifications also successfully discriminated between risk groups </plain></SENT>
<SENT sid="7" pm="."><plain>The new WHO subgroups [refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>), with (<z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e>) or without ringed sideroblasts] showed a significantly (P = 0.0454) different prognosis for OS, but not for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> (P = 0.0839), in comparison to the subgroups having erythroid <z:mpath ids='MPATH_589'>dysplasia</z:mpath> only (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain>Risk stratification into <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blast-I (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-I</z:e>) and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-II</z:e> tended to yield different prognoses for OS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The <z:e sem="disease" ids="C0349641" disease_type="Neoplastic Process" abbrv="">5q-minus syndrome</z:e> strongly predicted for a good prognosis </plain></SENT>
<SENT sid="10" pm="."><plain>In patients treated with the demethylating agent <z:chebi fb="0" ids="50131">decitabine</z:chebi> (n = 24), IPSS "poor risk" cytogenetics were unable to predict for the expected worse prognosis when compared to "intermediate-risk" cytogenetics </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, we confirm in a single-center patient cohort that the use of the WHO classification improves the predictive value of the FAB classification and that, in patients with cytogenetic data available, the IPSS can be used for clinical decision-making </plain></SENT>
</text></document>